Cargando…
Prospective Activity of PLG0206, an Engineered Antimicrobial Peptide, on Chronic Periprosthetic Joint Infection Total Knee Arthroplasty Components Ex Vivo: The Knee Explant Analysis (KnEA) Study
PLG0206 is an engineered antimicrobial peptide that has completed phase 1 clinical studies. A prospective study was completed on explanted implants from chronic periprosthetic joint infections (n = 17). At a concentration of 1 mg/mL for 15 min, there was a mean 4-log(10) reduction (range, 1 to 7) in...
Autores principales: | Huang, David, Parker, Dana M., Mandell, Jonathan B., Brothers, Kimberly M., Gish, Charles G., Koch, John A., Pachuda, Nicholas, Dobbins, Despina, Steckbeck, Jonathan, Urish, Kenneth L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Microbiology
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8612143/ https://www.ncbi.nlm.nih.gov/pubmed/34817227 http://dx.doi.org/10.1128/Spectrum.01879-21 |
Ejemplares similares
-
1040. Knee Explant Analysis (KnEA) Using PLG0206 in Periprosthetic Joint Infection (KnEA Study)
por: Huang, David, et al.
Publicado: (2021) -
The Engineered Antibiotic Peptide PLG0206 Eliminates Biofilms and Is a Potential Treatment for Periprosthetic Joint Infections
por: Huang, David, et al.
Publicado: (2021) -
Engineered peptide PLG0206 overcomes limitations of a challenging antimicrobial drug class
por: Huang, David B., et al.
Publicado: (2022) -
1070. In vitro Activity of PLG0206 Against Isolates Commonly Found in Periprosthetic Joint Infections (PJI)
por: Huang, David, et al.
Publicado: (2021) -
1098. A Phase 1 Safety and Tolerability of Single Ascending Doses of a Novel Engineered Cationic Peptide, PLG0206, in Healthy Subjects
por: Huang, David, et al.
Publicado: (2021)